Clinical Trial

InspireMD Announces Combined Financings of $58 Million

Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid StentMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc.…

5 months ago

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics,…

5 months ago

NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)…

5 months ago

Vericel Reports Second Quarter 2025 Financial Results

Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased…

5 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

5 months ago

Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms

Reduce development timelines and costs, while improving access to life-saving treatmentsVANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations…

5 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors…

5 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…

5 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private…

5 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43…

5 months ago